Rapid clearance of erythrodermic psoriasis with apremilast

BACKGROUNDApremilast is a new immunomodulatory drug, a small molecule inhibitor of PDE4, which down-regulates the expression of multiple pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 17, interleukin 23. MAIN OBSERVATIONSWe describe a case of a 54-year-old man with eryt...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatological case reports 2017, Vol.11 (2), p.29-31
Main Authors: Papadavid, Evangelia, Kokkalis, Georgios, Polyderas, Georgios, Theodoropoulos, Konstantinos, Rigopoulos, Dimitrios
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDApremilast is a new immunomodulatory drug, a small molecule inhibitor of PDE4, which down-regulates the expression of multiple pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 17, interleukin 23. MAIN OBSERVATIONSWe describe a case of a 54-year-old man with erythroderma in the course of psoriasis (PASI=49), with contraindications to other psoriasis therapies, in whom total clearance of skin lesions was achieved by day 20 after therapy with apremilast at a dose of 30 mg bid (ΔPASI = 100). The patient had a history of prior use of cyclosporine, methotrexate and adalimumab. His comorbidities included obesity, fatty liver and hypercholesterolemia. CONCLUSIONIn this case of erythroderma in the course of psoriasis apremilast led to total clearance of all cutaneous lesions.
ISSN:1898-7249
1898-7249
DOI:10.3315/jdcr.2017.1246